Clin2
NCT06337942Worth exploringRecruiting

Bladder or kidney-bladder transplant from a deceased donor

Bladder DiseaseBladder, NeurogenicBladder CancerKidney Failure

Part of Brain & nervous system, Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
5 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have a severe bladder problem (like a shrunken or poorly working bladder, or bladder cancer that has not spread to other parts of the body) that requires removal of the bladder.
  • You are already taking immune-suppressing medicines for a prior organ transplant, or you need both a new kidney and bladder.
  • You are willing and able to do clean intermittent catheterization (emptying your bladder with a tube) by yourself or with help.
  • You have no serious infections such as active HIV, hepatitis B or C, or untreated tuberculosis, and no bleeding disorders or connective tissue diseases like severe rheumatoid arthritis or Ehlers-Danlos syndrome.
  • You agree to be vaccinated against COVID-19 (or are already fully vaccinated and boosted).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06662071Recruiting
Personalized bladder cancer treatment using organoid drug testing

This trial tests if using a patient's own tumor cells grown in a lab (organoids) can help choose the best chemotherapy to put directly into the bladder. It is for people with non-muscle invasive bladder cancer who need their first round of this treatment.

Binzhou, Shandong
NCT07475403Recruiting· Phase 2
Immunotherapy guided by urine DNA for high risk bladder cancer

This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.

Tianjin
NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer

This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.

Shanghai, Shanghai Municipality
NCT06091124Recruiting· Phase 2
Immunotherapy plus chemo before surgery for neuroendocrine bladder cancer

This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.

Nanjing, Jiangsu
NCT07379255Recruiting
Organoid test to guide chemo after bladder cancer surgery

This trial uses a lab-grown version of your tumor (an organoid) to see which chemotherapy might work best for you after bladder cancer surgery. It helps doctors choose the most effective treatment for each person.

Jinan, Shandong
NCT04626167Recruiting· Early Phase 1
Testing a bladder transplant done with a kidney transplant

This early-phase study is testing a combined bladder and kidney transplant approach for people whose bladder problems damage the kidneys. The goal is to see if this treatment can improve bladder and kidney outcomes and be done safely.

Rochester, Minnesota

Hear when a new Bladder Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.